Hansa Medical Interim Report April – June 2016

MALMÖ, Sweden--(BUSINESS WIRE)--Regulatory News:

Hansa Medical (STO:HMED):

Second quarter in brief

Business highlights

›› US Food and Drug Administration (FDA) cleared Hansa Medical’s IND application for a study with IdeS in kidney transplantation
MORE ON THIS TOPIC